Vitiligo, Kybella top 2015 reads in Healio.com/Dermatology

Study findings on vitiligo treatment and comorbidities were among 2015’s most-read articles in Healio.com/Dermatology.

Other widely read articles during the year included the FDA approving Kybella for treating submental fat, Soolantra Cream for treating rosacea, and granting orphan drug designation to Humira for treating hidradenitis suppurativa:

Xeljanz might be effective as vitiligo treatment

Xeljanz was effective as treatment in a patient with vitiligo, according to recently published study results.

Brett A. King, MD, PhD, and Brittany G. Craiglow, MD, reported on a woman in her 50s who had widespread and progressive vitiligo for approximately 1 year. Triamcinolone ointment, 0.1% and tacroliumus ointment, 0.1% had been used as treatment with no effect. Read more

FDA grants orphan drug status to Humira for treatment of hidradenitis suppurativa

AbbVie announced in May that the FDA has granted orphan drug designation to Humira for treating moderate-to-severe hidradenitis suppurativa.

The supplemental biologic license application by Abbvie seeking the agency’s approval for the use of Humira (adalimumab) in patients with moderate-to-severe hidradenitis suppurativa (HS; Hurley Stage II and Hurley Stage III disease) is being reviewed by the FDA, according to a press release. Read more

FDA approves Galderma's Soolantra Cream for treatment of rosacea lesions

Galderma Laboratories announced that the FDA has approved Soolantra Cream for once-daily, topical treatment of inflammatory rosacea lesions, according to a press release.

Linda Stein Gold

“Rosacea is a common and challenging condition to manage as it tends to vary from patient to patient, often requiring a tailored approach. For that reason, we are always looking for innovative new treatments,” Linda Stein Gold, MD, a Galderma consultant and clinical investigator for the phase 3 studies of Soolantra Cream (ivermectin cream, 1%), said in the release. “While some rosacea treatments … may take more than 4 weeks to show effect, Soolantra Cream may provide initial results as early as week 2.” Read more

Research shows more than 20% of patients with vitiligo have at least one comorbid autoimmune disease

SAN FRANCISCO — More than 20% of patients with vitiligo in a Detroit hospital database had at least one comorbid autoimmune disease, according to research in a poster presentation at the American Academy of Dermatology Annual Meeting.

Iltefat Hamzavi

Iltefat Hamzavi, MD, FAAD, and colleagues searched the Henry Ford Medical Record Database to identify 1,873 patients with vitiligo who were seen between Jan. 1, 2002, and Oct. 31, 2012. Read more

FDA approves Kybella for treatment of submental fat

The FDA announced in April it approved Kybella, also known as ATX-101, for the treatment of moderate-to-severe submental fat in adults.

Kybella (deoxycholic acid, Allergan) is not approved nor recommended for treating fat outside the submental area, according to an FDA press release. With Perspectives. Read more